Search

Displaying results 5201 - 5210 of 10000 in total
  1. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid … It also has an effect on viral gp160 envelope protein. [A31692]

  2. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity. [A175642]

  3. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  4. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

  5. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. … M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.

  6. Drug

    Vercirnon

    go.drugbank.com/drugs/DB15250
    Investigational

    It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.

    International brands: Traficet-EN
  7. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

  8. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.

    Synonyms: 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
  9. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.

  10. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982) … Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.